Below is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
Clinical Trials
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the
This is a phase 3, randomized, multi-center study that will evaluate an active drug versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day
The objective of this study is to assess the efficacy and safety of an active drug for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy.
The objective of this study is to assess the efficacy and safety of an active drug combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe Atopic dermatitis (AD) who are candidates for
The objective of this study is to assess the efficacy and safety of an active drug for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.
This is an 88-week Phase 2b, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the safety and efficacy of an active drug in adult subjects with moderate to severe atopic dermatitis. In Period 1, subjects will be
Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on the use patterns and